Celgene executive Bob Hugin linked to alleged exploitation of Thalomid safety rules and FDA reprimands

Celgene executive Bob Hugin linked to alleged exploitation of Thalomid safety rules and FDA reprimands The passage identifies a senior Celgene executive (Bob Hugin, later a political figure) and describes alleged corporate strategies to market Thalomid for unapproved uses, citing FDA warning letters and a whistle‑blower lawsuit. It provides concrete names, dates, and documents (SEC filing, FDA letters) that could be pursued for deeper investigation, but the claims are largely based on publicly reported filings and lack new, undisclosed evidence. Key insights: Bob Hugin was a managing director at Celgene during a period of financial distress.; Celgene allegedly pursued off‑label promotion of Thalomid despite FDA restrictions.; The company hired 60 sales reps and sought FDA approval for multiple myeloma soon after launch.